Head-To-Head Analysis: REGENXBIO (NASDAQ:RGNX) & Zenas BioPharma (NASDAQ:ZBIO)

REGENXBIO (NASDAQ:RGNX) and Zenas BioPharma (NASDAQ:ZBIO) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, analyst recommendations, profitability, dividends and risk.

Profitability

This table compares REGENXBIO and Zenas BioPharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
REGENXBIO	-112.58%	-220.07%	-46.04%
Zenas BioPharma	N/A	-122.45%	-58.04%

Risk and Volatility

REGENXBIO has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500. Comparatively, Zenas BioPharma has a beta of -1.04, meaning that its stock price is 204% less volatile than the S&P 500.

Institutional and Insider Ownership

88.1% of REGENXBIO shares are held by institutional investors. 14.2% of REGENXBIO shares are held by company insiders. Comparatively, 22.0% of Zenas BioPharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings & Valuation

This table compares REGENXBIO and Zenas BioPharma”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
REGENXBIO	$170.44 million	3.38	-$193.88 million	($3.79)	-2.30
Zenas BioPharma	$10.00 million	210.47	-$377.74 million	($8.99)	-3.59

REGENXBIO has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations and price targets for REGENXBIO and Zenas BioPharma, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
REGENXBIO	1	3	9	0	2.62
Zenas BioPharma	1	2	6	0	2.56

REGENXBIO currently has a consensus target price of $23.27, suggesting a potential upside of 166.58%. Zenas BioPharma has a consensus target price of $45.71, suggesting a potential upside of 41.57%. Given REGENXBIO’s stronger consensus rating and higher possible upside, equities analysts clearly believe REGENXBIO is more favorable than Zenas BioPharma.

Summary

REGENXBIO beats Zenas BioPharma on 10 of the 14 factors compared between the two stocks.

About REGENXBIO

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

About Zenas BioPharma

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.